TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer

Cancer Research

Volumn 75, Issue 2, 2015, Pages 415-425

  McCarroll, Joshua A ^a,b   Gan, Pei Pei ^a   Erlich, Rafael B ^a   Liu, Marjorie ^a   Dwarte, Tanya ^a   Sagnella, Sharon S ^a,b   Akerfeldt, Mia C ^a   Yang, Lu ^a   Parker, Amelia L ^a   Chang, Melissa H ^a   Shum, Michael S ^a   Byrne, Frances L ^a   Kavallaris, Maria ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETAIII TUBULIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; PTEN PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR; SERPIN-B5; TUBB3 PROTEIN, HUMAN; TUBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOIKIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CARCINOGENICITY; CELL ADHESION; CELL MIGRATION; CELL SHAPE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR PROMOTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL GROWTH; CELL MOTION; ENZYMOLOGY; HUMAN; LUNG TUMOR; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANOIKIS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SERPINS; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUBULIN;

EID: 84920939099     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2740     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Aisner DL,Marshall CB. Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol 2012;138:332-46.
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
4. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10:194-204.
5. Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, et al. Crossvalidation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 2012;23:86-93.
6. Vilmar AC, Santoni-Rugiu E, Sorensen JB. Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 2011;17:5205-14.
7. Gan PP, McCarroll JA, Byrne FL, Garner J, Kavallaris M. Specific betatubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One 2011;6:e21717.
8. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther 2010;9:1339-48.
9. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67:9356-63.
10. McCarroll JA, Gan PP, Liu M, Kavallaris M. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 2010;70:4995-5003.
11. Egevad L, Valdman A, Wiklund NP, Seve P, Dumontet C. Beta-tubulin III expression in prostate cancer. Scand J Urol Nephrol 2010;44:371-7.
12. Katsetos CD, Draber P, Kavallaris M. Targeting betaIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anticancer Agents Med Chem 2011;11:719-28.
13. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44.
14. UnluM, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997;18:2071-7.
15. Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study. Proteomics 2006;6: 1681-94.
16. Byrne FL, Yang L, Phillips PA, Hansford LM, Fletcher JI, Ormandy CJ, et al. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. Oncogene 2014;33:882-90.
17. Sagnella SM, Duong H, MacMillan A, Boyer C, Whan R,McCarroll JA, et al. Dextran-based doxorubicin nanocarriers with improved tumor penetration. Biomacromolecules 2014;15:262-75.
18. Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T, et al. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 2003;22:6194-203.
19. Boyer C, Teo J, Phillips P, Erlich RB, Sagnella S, Sharbeen G, et al. Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. Mol Pharm 2013;10:2435-44.
20. Berardi R, Morgese F, Onofri A, Mazzanti P, Pistelli M, Ballatore Z, et al. Role of maspin in cancer. Clin Transl Med 2013;2:8.
21. Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, Lonardo F. Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology 2009;54:590-7.
22. Goulet B, Chan G, Chambers AF, Lewis JD. An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. Biochem Cell Biol 2012;90:22-38.
23. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
24. Elliott NT, Yuan F. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci 2011;100:59-74.
25. Mina LA, Sledge GW Jr. Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol 2011;8:325-32.
26. Sheng S, Qiao M, Pardee AB. Metastasis and AKT activation. J Cell Physiol 2009;218:451-4.
27. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
28. Katakura H, Takenaka K, Nakagawa M, Sonobe M, Adachi M, Ito S, et al. Maspin gene expression is a significant prognostic factor in resected nonsmall cell lung cancer (NSCLC). Maspin in NSCLC. Lung Cancer 2006;51:323-8.
29. Takanami I, Abiko T, Koizumi S. Expression of maspin in non-small-cell lung cancer: correlation with clinical features. Clin Lung Cancer 2008;9: 361-6.
30. Zheng HC, Saito H, Masuda S, Wang ZG, Takano Y. Cytoplasmic and nuclear maspin expression in lung carcinomas: an immunohistochemical study using tissue microarrays. Appl Immunohistochem Mol Morphol 2008;16:459-65.
31. Beltran AS, Blancafort P. Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics 2011;6:224-35.
32. Nam E, Park C. Maspin suppresses survival of lung cancer cells through modulation of Akt pathway. Cancer Res Treat 2010;42:42-7.
33. Kim S,Han J, Kim J, Park C. Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res 2004;64:6900-5.
34. Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S, et al. ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene 2008;27: 1045-54.
35. Neal CL, Henderson V, Smith BN, McKeithen D, Graham T, Vo BT, et al. Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells. BMC Cancer 2012;12:336.
36. De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, et al. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012;227:1034-41.
37. Mhaidat NM, Thorne RF, Zhang XD, Hersey P. Regulation of docetaxelinduced apoptosis of human melanoma cells by different isoforms of protein kinase C. Mol Cancer Res 2007;5:1073-81.
38. Bharadwaj S, Thanawala R, Bon G, Falcioni R, PrasadGL. Resensitization of breast cancer cells to anoikis by tropomyosin-1: role of Rho kinasedependent cytoskeleton and adhesion. Oncogene 2005;24:8291-303.
39. Qin L, Zhang M. Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway. J Biol Chem 2010; 285:32360-9.
40. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. Anoikis: an emerging hallmark in health and diseases. J Pathol 2012;226:380-93.
41. Zhong X, Rescorla FJ. Cell surface adhesion molecules and adhesioninitiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal 2012;24:393-401.
42. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-8.
43. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13:283-96.